Stamford Pharmaceuticals is a clinical-stage onco-dermatology company developing a novel treatment for basal cell carcinoma (BCC). Stamford today announced the appointment of Dr Edward McKenna and Mr Andrew Strong to the company’s board, marking a new phase of growth. “Stamford is excited to bring on both Dr Edward McKenna and Mr Andrew Strong to the company’s board. Both Dr McKenna and Mr Strong have deep industry experience and bring valuable complementary skills that will help us navigate our next phase of growth,” said Dr Clement Leong, PhD, Chief Executive Officer of Stamford.
Dr McKenna was most recently a Principal Medical Science Director at Genentech with responsibilities as the medical lead for dermatologic oncology and Zelboraf/Cotellic, Tecentriq and Erivedge. Mr Strong is a Pillsbury partner in the firm’s Houston and Austin offices. He has extensive experience representing many of the firm’s life sciences clients and advises on corporate and securities, mergers and acquisitions, and private and public financing. Mr Strong was also the Founding President and Chief Executive Officer of Kalon Biotherapeutics.